AcelRx Pharmaceuticals(US:ACRX)2025-11-12 21:12Financing and Cash Position - Talphera closed a $17 million first tranche financing led by CorMedix, with a total financing goal of up to $29 million[6]. - Cash and investments as of September 30, 2025, were $21.3 million, expected to be sufficient through a potential PMA approval of Niyad in late 2026[6]. - As of September 30, 2025, cash, cash equivalents, and investments increased to $21,289,000 from $8,863,000 as of December 31, 2024, representing a growth of 140.4%[17]. Clinical Studies and Development - Five of the nine target clinical study sites for the NEPHRO study are activated, with completion expected in H1 2026[6]. - The NEPHRO CRRT study aims to enroll 70 adult patients and has received central IRB approval[12]. - The company anticipates activating four additional target profile sites in Q4 2025 to accelerate enrollment in the NEPHRO study[2]. Financial Performance - Net loss from continuing operations for Q3 2025 was $4.4 million, compared to a net loss of $3.4 million in Q3 2024[6]. - Net loss per share attributable to common shareholders for Q3 2025 was $0.11, compared to $0.13 in Q3 2024[6]. - Combined R&D and SG&A expenses for Q3 2025 totaled $3.4 million, a decrease from $3.7 million in Q3 2024[6]. - For the three months ended September 30, 2025, total operating expenses were $3,423,000, a decrease of 8.7% from $3,749,000 in the same period of 2024[18]. - Research and development expenses for the three months ended September 30, 2025, were $1,803,000, down 12.2% from $2,053,000 in the prior year[18]. - Selling, general and administrative expenses decreased to $1,620,000 for the three months ended September 30, 2025, compared to $1,696,000 in 2024, a decline of 4.5%[18]. - Non-GAAP operating expenses for the nine months ended September 30, 2025, were $9,545,000, down 16.7% from $11,497,000 in the same period of 2024[18]. - Stock-based compensation expense for the three months ended September 30, 2025, was $152,000, a decrease of 35.0% from $234,000 in the same period of 2024[18]. Assets and Liabilities - Total assets rose to $30,742,000 in September 2025, up from $18,236,000 in December 2024, indicating a 68.5% increase[17]. - Total liabilities increased to $11,565,000 in September 2025, compared to $10,235,000 in December 2024, reflecting a rise of 13.0%[17]. - Total stockholders' equity surged to $19,177,000 in September 2025, up from $8,001,000 in December 2024, marking an increase of 139.7%[17]. Cost Management and Future Growth - Talphera expects cash operating expenses in the range of $14 million to $15 million for 2025, down from a previous estimate of $16 million to $17 million[5]. - The company continues to focus on cost management while investing in research and development to drive future growth[18]. - Talphera granted CorMedix the right to nominate a board member and the exclusive right of first negotiation for a potential acquisition[6].